Back to Search
PRITHA WORKMAN, M.D.
M.D.
Student in an Organized Health Care Education/Training Program
NPI: 1588007736IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
CMS Specialties
PrimaryOBSTETRICS/GYNECOLOGY
Education
UNIVERSITY OF CALIFORNIA, SAN DIEGO SCHOOL OF MEDICINE
Class of 2012
Research & Publications (20)
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
PMID 17513464·Ann N Y Acad Sci·2007
6-review
Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.
PMID 16670384·J Natl Cancer Inst·2006
6-review
Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics.
PMID 16869789·Cold Spring Harb Symp Quant Biol·2005
8-other
Drug discovery strategies: technologies to accelerate translation from target to drug.
PMID 15688601·J Chemother·2004
4-observational
Altered states: selectively drugging the Hsp90 cancer chaperone.
PMID 15106614·Trends Mol Med·2004
6-review
Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment.
PMID 15046615·Biochem Soc Trans·2004
6-review
Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
PMID 15013520·Cancer Lett·2004
6-review
Overview: translating Hsp90 biology into Hsp90 drugs.
PMID 14529382·Curr Cancer Drug Targets·2003
6-review
Strategies for treating cancers caused by multiple genome abnormalities: from concepts to cures?
PMID 14763125·Curr Opin Investig Drugs·2003
6-review
Larval behavior of four Culex (Diptera: Culicidae) associated with treatment wetlands in the southwestern United States.
PMID 14714671·J Vector Ecol·2003
7-preclinical
The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
PMID 12819933·Cancer Chemother Pharmacol·2003
6-review
How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development.
PMID 12678873·Curr Pharm Des·2003
6-review
Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.
PMID 12589030·Mol Cancer Ther·2003
6-review
Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone.
PMID 12507224·Cancer Detect Prev·2002
6-review
The impact of genomic and proteomic technologies on the development of new cancer drugs.
PMID 12401677·Ann Oncol·2002
6-review
Translating basic cancer research into new cancer therapeutics.
PMID 11927279·Trends Mol Med·2002
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 W ARBOR DR # MC8433, UCSD
SAN DIEGO, CA 92103 - Phone
- (618) 543-6922
Quick Facts
- NPI
- 1588007736
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 14
- Publications
- 20
Are you this provider?
Claim Your Profile